International Journal of Multidisciplinary Sciences and Arts

E-ISSN : 2962-1658
Volume 4, Number 3, July , 2025
https://doi.org/10.47709/ijmdsa.v4i3.5291

The Role of Artificial Intelligence in Diagnosing Drug-Induced Hepatitis: A Systematic Review on Differentiation from Viral Hepatitis

Syed Umer Hasan[1*], Samesh Kumar[2], Ashish Shiwlani[3], Sooraj Kumar[4], Nitasha Shiwlani[5]
[1]Fitchburg State University, USA, [2]Georgia Institute of Technology, [3]Illinois Institute of Technology, Chicago, Illinois, USA, [4]DePaul University Chicago, [5]Freelance researcher
[1]shasan1@student.fitchburgstate.edu, [2]skumar649@gatech.edu, [3]shiwlaniashish@gmail.com, [4]skumar48@depaul.edu

***Corresponding Author**

Article History:
Submitted: 10-01-2025
Accepted: 06-04-2025
Published: 18-09-2025

Keywords:
Drug-Induced Liver Injury DILI); Artificial Intelligence (AI); Viral Hepatitis Diagnosis; Machine Learning Algorithms.

The Journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0).

ABSTRACT

DILI presents symptoms like those in viral hepatitis in terms of elevated liver enzymes, jaundice, and liver dysfunction. These make it rather difficult to differentiate between DILI and viral hepatitis through traditional diagnostic methods. DILI is of profound relevance to global morbidity and mortality today. Thus, accurate diagnosis in terms of time and precision is essential. AI offers hope and promises to use improved diagnostics for personalized treatment strategies. After a systematic search on PubMed and Google Scholar, 933 studies were identified, and they concentrated on AI applications in differentiation regarding DILI and viral hepatitis. Only 55 studies were shortlisted for evaluation via a review process that covered diverse AI techniques deployed in diagnosis, including performance metrics. Models, AI have improved how DILI is diagnosed into a paradigm of distinctive biomarkers in a cross-section of clinical data. Machine learning algorithms using clinical data and imaging have very high accuracy in distinguishing DILI from viral hepatitis. It will improve early diagnosis, prognostic predictions, and novel therapeutic target identification by AI with multimodal-data cross-images, laboratory tests, and clinical history. Indeed, AI has the potential to be instrumental in enhancing the diagnosis of DILI and its differentiation from viral hepatitis. With the development of further advanced models, AI could even act as predictive compared to giving the facilities for drug-induced hepatotoxicity and thus enhance patient outcomes while reducing the cost-benefits for richer pharmaceutical processes.

INTRODUCTION

Background of DILI

Drug-induced liver injury (DILI) continues to be one of the most significant causes of morbidity and mortality, in turn contributing to the impact that acute liver failure is having globally. DILI has proven to be quite complex and multifactorial, pertaining to damage to the liver related to medication or toxin ingestion. While the liver is one of the few resilient organs that can regenerate, certain drugs can induce severe hepatotoxicity in a dose-dependent or prolonged manner for which the liver fails. Countries expose a variation in the incidence of DILI. Still, it is well recognized as a likely potential reason for liver transplantation in several countries and a more commonly reported reason for withdrawal from drug markets. For instance, acetaminophen, which is one of the most used analgesics, is among the frequent causes of drug-induced hepatotoxicity (Yen et al., 2021). Furthermore, the clinical picture is often relatively nonspecific, resembling other liver conditions, such as viral hepatitis, alcoholic liver disease, or autoimmune hepatitis, all of which complicate diagnosis overall, particularly regarding timely and proper diagnosis, further delaying treatment and potentially leading to worse outcomes for the patient.

The most common clinical conundrum in hepatology is the distinction between drug-induced hepatitis (DIH) and viral hepatitis, especially considering the rising incidence of viral hepatitis on a global level. Both symptoms have similar clinical manifestations of jaundice, increased liver enzymes, and fatigue. The existence of uncertainty in diagnosis becomes all the more difficult by the absence of a definite, simple, and widely available marker for DILI. Indeed, a lot of DILI diagnoses rely on patient history, involvement of other causes, and liver biopsy-an invasive and risky process. Therefore, there is a pressing need for more reliable, efficient, and non-invasive methods for distinguishing DILI from viral hepatitis, and identifying early-stage liver injury to prevent progression to acute liver failure.

AI in Medicine

Artificial intelligence had revolutionized much in healthcare diagnostics, predictive modeling, and clinical decision support. AI-enabled instruments can scour huge data files and identify patterns and correlations that may be

This is an Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

E-ISSN : 2962-1658
Volume 4, Number 3, July , 2025
https://doi.org/10.47709/ijmdsa.v4i3.5291

missed by human clinicians themselves. Artificial intelligence is adopted in several fields of medicine, from radiology to pathology and personalized medicine, to drug development. The evolution of AI includes the development of algorithms that can analyze imaging data, clinical histories, and even genetic data, which in turn helped to develop diagnostic models that are faster and more accurate than conventional methods.

In recent years, the role of artificial intelligence in hepatology has multiplied. AI models, especially those who use machine-learning (ML) and deep-learning (DL) implementations, have demonstrated potential to identify cases of liver diseases such as cirrhosis, NAFLD and HCC. AI integration-a technique that can process any number of multi-modalities like imaging, laboratory tests, and clinical eye data into a single platform-will make way for early diagnosis, better prognostic predictions, and identification of new therapeutical targets. DILI diagnosis will be much faster and greater when using AI-using tools against liver injuries. In addition, they would also withhold information from viral hepatitis. DILI would provide unique biomarkers or patterns of liver injury characteristic of damage from drugs (Vall et al., 2021).

In addition to this, it is emerging slowly yet importantly that AI is starting to occupy that key position for predicting future adverse drug reactions, DILI being one of them, by elbowing such potentially toxic drugs out before they enter the market. Predictive AI models can be developed that may include chemical structure information, genetic factors, and patient data to predict which compounds are likely to be a risk for the liver. This could aid in forecasting DILI incidents and minimizing post-market surveillance. For example, sophisticated machine learning models would apply to predicting liver toxicity by the drug's molecular characteristics, a vital input for the pharmaceutical sector while developing drugs (Liu et al., 2021).

Objective and Research Questions

The purpose of this systematic review is to study AI's role in the enhancement of detection and differentiation of drug-induced hepatitis (DIH) from a viral one. In more specific terms, this article will focus on the capability of AI in detecting drug-induced liver injury from clinical, imaging, and laboratory data and using advanced diagnostic algorithms to differentiate this condition from viral hepatitis. This review will describe the current state of the art of AI in DILI Diagnosis, analyzing the strengths and weaknesses of this model as well as its future promises in clinical hepatology.

Key research questions include:

RQ 1: How effective are AI algorithms in detecting drug-induced hepatitis (DIH) using clinical, imaging, and laboratory data?

RQ 2: To what extent can AI distinguish DIH from viral hepatitis through advanced diagnostic algorithms?

RQ 3: What are the strengths and limitations of AI in improving the diagnostic accuracy of liver injuries, and how can these models reduce reliance on invasive procedures like liver biopsies?

RQ 4: What are the potential future directions for AI in liver disease diagnostics, particularly in distinguishing between different etiologies of liver injury, such as drug-induced and viral hepatitis?

As Artificial Intelligence continues to improve the standards for diagnosis and management of liver diseases, we would also expect the next generation of AI-based tools to enhance accuracy, speed, and cost reduction for diagnosis. It is expected that incorporation of AI-powered artificial intelligence into a clinical environment would contribute to lesser diagnostic ambiguities, improvement in patient care, and lessening of liver disease-related health resource burden including DILI. Some of these challenges include the creation of reproducible AI models, availability of good datasets, and the development of regulatory frameworks that will allow safe and ethical practice of this technology in real-life clinical settings (Liu et al., 2022).

This review will amalgamate the recent advances into applications of AI in drug-induced liver injury detection into vital high-value input into the developing dynamics of AI in hepatology and pave the way for future revolutions and advancements in liver disease diagnostics.

METHOD

This systematic review was guided by the PRISMA 2020 principles. The review dealt with the application of Artificial Intelligence (AI) in differentiating and classifying Drug-Induced Liver Injury (DILI) within the scope of viral hepatitis, namely, Hepatitis B and C. The articles considered fall between the years 2015-2024. It comprised a systematic review of four key steps: identification, screening, eligibility, and inclusion.

Step 1: Identification

The identification phase forms the pivotal point of the review, basically, where they will select relevant studies identified for this review. So, the main search was done across major databases such as PubMed and Google Scholar to cover a large bulk of the studies on the application of AI with DILI concerning viral hepatitis. Boolean operators were employed in the search strategy to refine and narrow down the results within the scope of the very relevant studies. The search string used for this purpose was:

This is an Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

International Journal of Multidisciplinary Sciences and Arts
E-ISSN : 2962-1658
Volume 4, Number 3, July , 2025
https://doi.org/10.47709/ijmdsa.v4i3.5291

("Artificial Intelligence" OR "Machine Learning") AND ("Hepatitis B Virus" OR "Hepatitis C Virus") AND ("Hepatocellular Carcinoma" OR "Liver Cancer") AND ("Early Detection" OR "Disease Progression") AND ("Medical Imaging" OR "Biomarkers") AND ("Sensitivity" OR "Specificity" OR "AUC")

The total of this search gives 933 studies: 151 from PubMed and 782 from Google Scholar. These works would be organized for the next actions within the review process.

Step 2: Screening

In the screening phase, the titles and abstracts for the papers identified were evaluated by two independent researchers for relevance. Studies were determined to be included if they mentioned some AI techniques applied to differentiate or classify DILI, specifically concerning hepatitis. Papers were excluded from further scrutiny if they did not consider AI or hepatitis injury to the liver or if they did not represent either classification or differentiation as related to DILI. If there were any disagreements between the two reviewers, it was deliberated among them to reach a consensus and then, if need be, a third reviewer joined them. This process led to selecting 55 papers that proceeded to the eligibility screening stage.

Step 3: Eligibility Criteria

The eligibility criteria were defined as a priori to ensure that only studies of the utmost relevance and scientific rigour were included (Brony et al., 2024; Gui et al., 2024). They were explicitly directed towards studies that addressed the AI differentiation of DILI in cases of hepatitis. A summary of the criteria is presented in Table 1.

Table 1: Eligibility Criteria for Review

Criteria	Inclusion	Exclusion
Timeframe	Studies published between 2015 and 2024	Studies published before 2015
Peer-Reviewed	Only peer-reviewed articles	Non-peer-reviewed articles, preprints, grey literature
Focus Area	AI applications in DILI related to hepatitis	Studies not focusing on DILI or hepatitis
Performance Metrics	Studies reporting metrics such as sensitivity, specificity, AUC	Studies lacking performance metrics
Language	English or translatable into English	Non-translatable languages

Step 4: Inclusion

After the eligibility assessment, a selection of 55 studies was made for detailed data extraction. Data that were obtained from each of the included papers included research objectives, AI methodologies adopted, datasets used, performance metrics stated (in terms of sensitivity, specificity, AUC), and the clinical relevance of findings. This information was synthesized to determine the overall impact and effectiveness of AI in differentiating and diagnosing DILI, especially for salivary and other viral hepatitis. Figure 1 demonstrates the selection and inclusion of studies according to PRISMA.




Figure 1. PRISMA Flowchart for Study Selection

This is an Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

E-ISSN : 2962-1658
Volume 4, Number 3, July , 2025
https://doi.org/10.47709/ijmdsa.v4i3.5291

Databases and Search Strategy

The literature search was carried out under PubMed and Google Scholar, the two most important databases on research coverage in AI and studies on hepatology. The search was refined further, using the Boolean operators and narrowing the focus to research into AI applications in DILI, hepatitis B and C, and important biomarkers. The strategy was made to catch every possible relevant study. Details of the search process and keywords used are summarized in Table 2.

Table 2. Summary of Search Strategy and Keywords

No.	Construct	Search Field/Limits
#1	"Artificial Intelligence" OR "Machine Learning"	TS=Topic
#2	"Drug-Induced Liver Injury" OR DILI OR "Drug-Induced Hepatitis"	TS=Topic
#3	"Viral Hepatitis" OR "Hepatitis B" OR "Hepatitis C"	TS=Topic
#4	"Differentiation" OR "Distinction" OR "Classification" OR "Diagnosis"	TS=Topic
#5	"Biomarkers" OR "Predictive Models"	TS=Topic
#6	"Sensitivity" OR "Specificity" OR "AUC"	TS=Topic
#7	2020–2024	PY=Year Published
#8	#1 AND #2 AND #3 AND #4 AND #5 AND #6	Language: English

Search Methodology

The search process was conducted in three distinct stages: (Jiaqing et al., 2023; Brony et al., 2024)

- **Initial search:** This included a comprehensive search across the databases to get a pool from which potentially relevant articles could be identified. It was done using the preestablished Boolean terms and criteria**.**
- **Screening:** The second stage is a comprehensive screening process, which involves reviewing titles and abstracts to determine whether they relate to AI techniques for differentiating or classifying DILI (Drug-Induced Liver Injury)-related to hepatitis**.**
- **Full-Text Review:** The remaining articles were thoroughly reviewed in the third and final stage. Each study was analyzed in detail to assess its relevance, methodology, and contribution to the research area. The full-text review ensured that only high-quality, relevant findings were included in the final analysis.

Data Extraction and Analysis

Data was extracted by collecting essential details from every paper, such as the key objectives, AI techniques, such as machine learning and deep learning, the used datasets, and the recorded performance metrics, including sensitivity, specificity, and area under the curve (AUC). All the data extracted were divided into major categories: the aim and objective of the study, AI methodology, dataset specification, and clinical relevance.

The quantitative analysis aimed at examining the performance measures recorded among studies (sensitivity, specificity, AUC, for example) so that the efficiency of various AI models could be determined. Thus, patterns were established in AI performance across studies, implying which models were relatively more efficacious in diagnosing DILI.

Qualitative analysis, on the other hand, will cover many of the issues in the genre, such as biases in datasets, lack of standardization of data, and the limitations of the current AI models. Further, the review will touch on the issue of how explainable AI will be in medical diagnostics and the possible bottlenecks toward the successful uptake of AI in clinical settings. Besides that, this review talked about the clinical applicability of the AI models discussed in the studies, which evaluated whether they can be used to improve the diagnosis and treatment of drug-induced liver injury in patients suffering from drug-induced liver injury due to hepatitis.

After the research allows an analysis like that done by Dharejo et al. (2023), this would lead to the synthesis of findings into a predetermined report that would talk about the promise of artificial intelligence in diagnosing DILI, the present challenges and future research directions. It would provide a thorough snapshot of the state of artificial intelligence in hepatology that is concerned with deciphering and diagnosing drug-induced liver injuries with a viral hepatitis association.

RESULT

Most of the studies have focused on predictive modelling using machine learning to predict drug-induced liver injury (DILI) through molecular structure, deep learning, ensemble methods, etc., or to highlight the growing importance of AI/ML in either predictive or mechanistic aspects of DILI. This table provides an overview of the design of the studies, AI/ML technologies adopted, and the significant findings and conclusions from the selected papers.

Tabel 3. significant findings and conclusions from the selected papers

Author(s) & Year	Title	Type of Study Design	AI/ML Method Used	Key Finding	Conclusion
Yen et al. (2021)	An artificial intelligence	Predictive Model	AI Algorithm (not specified)	AI-based algorithm was	The study demonstrates

This is an Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

E-ISSN : 2962-1658
Volume 4, Number 3, July , 2025
https://doi.org/10.47709/ijmdsa.v4i3.5291

	algorithm for analyzing acetaminophen-associated toxic hepatitis			successful in predicting and analyzing acetaminophen-induced liver damage. The model outperformed traditional diagnostic methods.	that AI can provide more accurate and faster predictions for acetaminophen-induced liver toxicity compared to conventional methods, enhancing clinical decision-making.
Villanueva-Paz, M., et al. (2021)	Critical review of gaps in the diagnosis and management of drug-induced liver injury associated with severe cutaneous adverse reactions	Review	N/A	Identifies gaps in the diagnosis and management of drug-induced liver injury (DILI) linked to severe skin reactions	Calls for improved diagnostic techniques and more personalized treatment strategies to reduce the risks of DILI associated with cutaneous reactions.
Kurosaki, K., & Uesawa, Y. (2022)	Development of in silico prediction models for drug-induced liver malignant tumors based on the activity of molecular initiating events	Experimental (In Silico)	Molecular Initiating Events-based Prediction	Developed models to predict drug-induced liver tumors, using molecular initiating events as key features	Suggests that in silico models can provide biologically interpretable features for predicting drug-induced malignant tumors.
Rao, M., et al. (2023)	AI/ML Models to Predict the Severity of Drug-Induced Liver Injury for Small Molecules	Experimental (AI/ML Models)	Machine Learning Models	Focused on predicting the severity of DILI for small molecules using AI/ML models	Concludes that AI/ML models significantly enhance the prediction of DILI severity, providing insights into safer drug development.
Kang, M. G., & Kang, N. S. (2021)	Predictive Model for Drug-Induced Liver Injury Using Deep Neural Networks Based on Substructure Space	Experimental (Deep Learning)	Deep Neural Networks	Developed deep learning models to predict DILI using chemical substructure space	Demonstrates the potential of deep neural networks for DILI prediction based on chemical substructure space, offering an advanced predictive tool.

This is an Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Su, et al. (2019)	Developing a Multi-Dose Computational Model for Drug-Induced Hepatotoxicity Prediction Based on toxicogenomic Data	Computational Modeling / Toxicogenomic Analysis	Multi-dose computational model, Random Forest, Support Vector Machine (SVM)	The multi-dose model predicts drug-induced hepatotoxicity with high accuracy, using toxicogenomic data.	The model offers a promising approach for predicting drug-induced hepatotoxicity, demonstrating potential in drug safety assessments.
Lewis, et al. (2024)	Diagnosis, prevention and risk-management of drug-induced liver injury due to medications used to treat mycobacterium tuberculosis	Clinical Review / Risk Management	Not explicitly mentioned; focuses on clinical risk management, diagnosis, and prevention strategies.	Drug-induced liver injury (DILI) risk varies among tuberculosis medications; proper risk assessment and prevention strategies are crucial.	The review emphasizes the importance of diagnosing, preventing, and managing DILI, recommending specific approaches for tuberculosis treatments.
Mohsen, et al. (2021)	Deep learning prediction of adverse drug reactions in drug discovery using open TG–GATEs and FAERS databases	Data-driven Drug Discovery, Adverse Reaction Prediction	Deep Learning, Neural Networks (specifically CNN, LSTM)	Deep learning models predict adverse drug reactions (ADRs) accurately by analyzing data from TG-GATEs and FAERS databases.	The study demonstrates that deep learning models can effectively predict ADRs, providing a valuable tool for drug safety in early-stage drug discovery.
Tang et al. (2023)	Exploring the Hepatotoxicity of Drugs through Machine Learning and Network Toxicological Methods	Predictive Model	Machine Learning, Network Toxicology	The study identified key factors and molecular interactions contributing to drug-induced hepatotoxicity, using machine learning and network methods.	Machine learning and network toxicological methods offer powerful tools to better predict and understand drug-induced liver injuries, improving drug safety assessments in clinical settings.
Lu et al. (2024)	Artificial Intelligence in Liver Diseases: Recent Advances	Review and Analysis	AI Methods in Liver Disease Research	AI has been increasingly applied to various liver diseases, including hepatocellular carcinoma, fibrosis, and drug-induced liver injury, leading to	AI technologies hold great promise for revolutionizing liver disease diagnosis and treatment, offering earlier detection and personalized therapeutic options.

This is an Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

E-ISSN : 2962-1658
Volume 4, Number 3, July , 2025
https://doi.org/10.47709/ijmdsa.v4i3.5291

				significant diagnostic improvements.	
Jiang et al. (2023)	Unraveling the mechanisms underlying drug-induced cholestatic liver injury: identifying key genes using machine learning techniques on human in vitro data sets	Mechanistic Study	Machine Learning (Gene Identification)	The study used machine learning to identify genes involved in drug-induced cholestatic liver injury, offering insights into the underlying mechanisms of toxicity.	Machine learning can be a valuable tool in unraveling complex disease mechanisms and identifying therapeutic targets, enhancing precision medicine for liver injury.
Adeluwa (2021)	Using Machine Learning On Diverse Datasets To Predict Drug-Induced Liver Injury	Predictive Model	Machine Learning (Various algorithms)	This thesis explored various machine learning models to predict drug-induced liver injury from diverse datasets.	The findings indicate that machine learning can effectively predict liver injury across a range of drugs, contributing to more robust screening systems in drug development.
Li (2021)	Predicting Drug-Induced Liver Injury With Artificial Intelligence	Predictive Model	AI Methods (Machine Learning)	This dissertation explored the use of AI to predict drug-induced liver injury (DILI), demonstrating its potential to forecast adverse reactions in clinical practice.	AI-based methods have strong potential to predict DILI, which can significantly aid clinicians in avoiding toxic drugs and managing patient care more effectively.
Hussin et al. (2021)	Handling imbalance classification virtual screening big data using machine learning algorithms	Data Classification	Machine Learning (Various algorithms)	The study explored methods to handle imbalanced classification problems in big data, improving the performance of machine learning models in screening virtual datasets.	Proper handling of imbalanced datasets can enhance the performance of machine learning models in virtual drug screening, making them more reliable in predicting toxicity and safety.
Jin et al. (2022)	Recognition of specific types of drug-induced	Predictive Model	Machine Learning (Random	The study showed that the random forest	The study suggests that the random forest

This is an Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

E-ISSN : 2962-1658
Volume 4, Number 3, July , 2025
https://doi.org/10.47709/ijmdsa.v4i3.5291

	liver injury using random forest algorithm: the importance of individual serum bile acid level		Forest)	algorithm could successfully classify types of drug-induced liver injury using individual serum bile acid levels as key features.	algorithm could be an effective tool for classifying and diagnosing specific drug-induced liver injuries, aiding in targeted treatment decisions.
Fu et al. (2023)	Clinic-radiomics model using liver magnetic resonance imaging helps predict chronicity of drug-induced liver injury	Predictive Model	Radiomics, Machine Learning	The clinic-radiomics model combining liver MRI with machine learning effectively predicted the chronicity of drug-induced liver injury.	Integrating radiomics with AI can improve the accuracy of diagnosing and predicting the progression of drug-induced liver injury, potentially leading to better patient management.
Moore et al. (2021)	Machine Learning to Identify Interaction of Single-Nucleotide Polymorphisms as a Risk Factor for Chronic Drug-Induced Liver Injury	Observational Study	Random Forest, Support Vector Machine	Identified SNPs related to DILI risk in patients with chronic liver disease.	SNP interaction may be a useful risk factor for DILI prediction.
Su et al. (2019)	Developing a Multi-Dose Computational Model for Drug-Induced Hepatotoxicity Prediction Based on Toxicogenomics Data	Computational Modeling Study	Support Vector Machine (SVM)	Developed a multi-dose computational model to predict drug-induced hepatotoxicity.	Multi-dose modeling aids in improving DILI prediction accuracy.
Puri (2020)	Automated Machine Learning Diagnostic Support System as a Computational Biomarker for Detecting Drug-Induced Liver Injury Patterns in Whole Slide Liver Pathology Images	Diagnostic Support System Study	AutoML, Convolutional Neural Network (CNN)	Used pathology images to detect DILI patterns.	The diagnostic system shows promise as a computational biomarker for DILI detection.

This is an Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

E-ISSN : 2962-1658
Volume 4, Number 3, July , 2025
https://doi.org/10.47709/ijmdsa.v4i3.5291

Datta et al. (2021)	Machine learning liver-injuring drug interactions with non-steroidal anti-inflammatory drugs (NSAIDs) from a retrospective electronic health record (EHR) cohort	Retrospective Cohort Study	Random Forest, Decision Trees	Identified liver-injuring NSAID interactions from patient data.	ML-based model predicts NSAID-induced liver injury with high accuracy.
Kim et al. (2021)	Machine Learning Approaches to Predict Hepatotoxicity Risk in Patients Receiving Nilotinib	Cohort Study	Gradient Boosting Machine, Logistic Regression	Developed models to predict hepatotoxicity risk in patients using Nilotinib.	Machine learning models showed good predictive performance for DILI risk in Nilotinib users.
Hong et al. (2017)	Development of Decision Forest Models for Prediction of Drug-Induced Liver Injury in Humans Using A Large Set of FDA-approved Drugs	Cross-sectional Study	Decision Forest, Random Forest	Created decision forest models using FDA-approved drugs to predict DILI.	The model demonstrated high prediction accuracy for various drugs.
Minerali et al. (2020)	Comparing machine learning algorithms for predicting drug-induced liver injury (DILI)	Comparative Study	Multiple ML Algorithms (Random Forest, SVM, etc.)	Compared different ML algorithms for DILI prediction.	Random Forest and Gradient Boosting performed best in predicting DILI.
Zhong et al. (2021)	Predicting Antituberculosis Drug–Induced Liver Injury Using an Interpretable Machine Learning Method: Model Development and Validation Study	Model Development Study	Interpretable ML Models (XGBoost, SHAP)	Developed interpretable ML models for predicting TB drug-induced liver injury.	Interpretable models help in understanding the underlying risk factors of DILI.
Xiao et al. (2024)	Interpretable machine learning in predicting drug-induced liver injury among tuberculosis patients: model development	Model Development Study	XGBoost, SHAP	Developed an interpretable ML model for TB drug-induced liver injury prediction.	The interpretable model provides transparency and improves clinical decision-making.

This is an Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

E-ISSN : 2962-1658
Volume 4, Number 3, July , 2025
https://doi.org/10.47709/ijmdsa.v4i3.5291

	and validation study

DISCUSSION

Background and Diagnostic Challenges in Hepatitis

- **Drug-Induced Hepatitis (DIH)**

Drugs due to adverse effects are the cause of liver damage-induced hepatitis (DIH). The liver is the primary site of drug metabolism and detoxification. When a drug enters the liver, it undergoes a metabolic transformation, mainly through the cytochrome P450 enzymes, converting it into reactive metabolites detrimental to the liver cells. The range of severity of DIH applies, that is, from the mildest enzyme elevation to acute liver failure, with such an event having a fatal consequence if not quickly managed (Liu et al., 2022).

Thus, common drugs causing hepatitis include acetaminophen, non-steroid anti-inflammatory drugs (NSAIDs), and antibiotics. Among the above, acetaminophen in increased doses is the best-known cause of acute liver failure (Yen et al., 2021). Ibuprofen and diclofenac NSAIDs can induce liver damage in an immune-mediated process, leading to idiosyncratic severe reactions (Jaganathan et al., 2021). Amoxicillin-clavulanate is typical of the class of antibiotics but has the highest variation of liver damage outcomes from its mild enzyme rise to that of the acute cholestatic hepatitis category (Zhan et al., 2022).

The biomarker's quantification procedure supports Biomarkers Associated with DIH The diagnosis of DIH. Significant markers of liver injury are alanine aminotransferase (ALT) and aspartate aminotransferase (AST); hence, these enzymes increase concentration in blood as liver cells undergo damage. Another important indicator is bilirubin, which results from haemoglobin degradation; thus, its increased levels indicate hepatic dysfunction or bile duct obstruction. In more severe cases, a liver biopsy may be performed to assess the magnitude of liver damage, but this procedure has its limitations in an acute setting (Wu et al., 2023).

- **Viral Hepatitis**

Viral hepatitis states several viral liver infections by viruses, such as Hepatitis A, Hepatitis B, and Hepatitis C. Each type has characteristics concerning its transmission, severity, and chronicity. Hepatitis A is mostly caused by oral ingestion of contaminated food and water; it is usually self-limiting and is expected to end with a good prognosis. Chronic liver disease does not occur because of such infection. Hepatitis B is a blood-and bodily-fluid-borne infectious disease. It can cause both acute and chronic infections, with chronic infection in the case of hepatitis B progressing to cirrhosis and subsequently to liver cancer. Therefore, it has become one of the major health concerns worldwide. Like hepatitis B, hepatitis C is mainly blood-borne. In many cases, the infection stays chronic and may finally produce cirrhosis and hepatocellular carcinoma (HCC) several years later. Unlike hepatitis B, hepatitis C does not have a vaccine currently available, but antiviral treatments have improved patient outcomes (Liu et al., 2021).

Viral hepatitis is diagnosed using serological tests to detect the corresponding antibodies and antigens against a particular virus in addition to PCR techniques for detection of the respective viral RNA or DNA in the exposed subject. For instance, Hepatitis A is diagnosed by the finding of anti-HAV IgM antibodies in the serum, indicative of a recent infection, while Hepatitis B is diagnosed by the antigen-having surface of the Hepatitis B through HBsAg and by the antibodies to core antigen using anti-HBc; for Hepatitis C, diagnosis is made by the detection of anti-HCV antibodies, confirmed by subsequent HCV RNA PCR tests. Chronicity and severity, on the other hand, are usually assessed through measures of liver enzymes, bilirubin levels, and imaging procedures, including elastography (Xiao et al., 2024). One of the prime barriers in terms of differential diagnosis regarding liver diseases such as DIH and viral hepatitis is the symptomatic overlap in clinical presentations. The symptoms can include jaundice, abdominal pain, or nausea and elevations in the levels of liver enzymes (ALT, AST) in both cases. These symptoms are nonspecific and thus make it difficult to differentiate between both based on clinical examination or laboratory findings. Furthermore, some medicinal compounds have the potential to mimic viral infections such that when liver injury progresses to cholestasis, both conditions have elevated bilirubin levels and exhibit similar clinical features (Vall et al., 2021).

- **Limitations of Traditional Diagnostics**

There are several drawbacks to traditional diagnostic methods like liver biopsy and serological tests. While liver biopsy is considered the gold standard to assess the damage of a liver, it is invasive and has risks resulting from bleeding or infection. In acute DIH, biopsy becomes challenging to perform as liver failure progresses very rapidly. Moreover, serological tests for viral hepatitis can be used readily, but they do not tell whether the virus is actively infecting a patient without extra PCR-based work-up. This becomes a significant problem when the patient has both DIH and viral hepatitis. The clinical picture becomes complicated (Gonzalez-Jimenez et al., 2021). A new dimension adding to the complexity of liver disease diagnosis has been the growing use of multiple drugs by patients, thus making it more difficult to isolate an injury's specific cause without the use of highly sophisticated diagnostics.

Diagnosis of drug-induced hepatitis from viral hepatitis remains a big challenge, given the overlapping clinical features and intrinsic limitations of traditional diagnostic methods. Biomarkers, such as ALT, AST, and bilirubin, are of immense use when indicating liver injury but cannot truly differentiate between the different causative agents of liver diseases. However, newer modalities like machine learning and AI-based predictive models have a good scope for

This is an Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

E-ISSN : 2962-1658
Volume 4, Number 3, July , 2025
https://doi.org/10.47709/ijmdsa.v4i3.5291

improving truth in these diagnoses by including wider clinical and molecular data (Liu et al., 2021; Wu et al., 2023).

The Role of AI in Identifying Drug-Induced Hepatitis (DIH)

- **AI in Biomarker Discovery**

Machine learning, part of artificial intelligence, is gaining increasing ground in identifying disease-specific biomarkers on Drug Induced Hepatitis (DIH). Traditional biomarker identifications are based on a slow, tedious and very error-prone process of scanning clinical data and laboratory results. Well, ML algorithms can do this faster and in turn detect very subtle patterns that the naked eye or the human analyst might not be able to immediately see. Thereafter, with analysis of large datasets of cases of this liver injury, algorithms will be able to come up with innovative biomarkers for DIH that could indicate such an injury earlier than currently used biomarkers and hence improve the accuracy and timeliness of diagnosis (Wang et al., 2022; Zhao et al., 2024). For instance, several studies have reported that specific drug exposures affect gene expression profiles, serum protein levels, and metabolomic changes and can, therefore, be potential DIH biomarkers.

In addition, support vector machines (SVM) and other ML models are also employed to investigate drug-liver injury associations with the aim of establishing biomarkers that would solely putatively associate with DIH. According to reports, data from various microarray analyses have been used to discover a number of promising novel biomarkers tied to the molecular mechanisms of DIH (Wang et al., 2022). ML approaches ensure more accurate discrimination of the biomarkers associated with DIH and those related to other liver ailments. For instance, the possible link with viral hepatitis. Especially because both DIH and viral hepatitis share the same biomarkers, such as ALT, AST, and bilirubin elevation levels, therefore, differentiating it from other liver diseases poses a challenge. AI can bring greater value in differentiating these two diseases by looking beyond diagnostic data and searching for pattern differences for each of the diseases. AI models can use clinical data, biomarker profiles, and genotypic information in order to enhance the diagnosis-making process, hence helping clinicians avoid misdiagnosis according to Jaganathan et al 2021. For instance, machine learning-based algorithms have been applied to large databases of patients, which themselves have at most a minuscule number of individuals. They are then provided with a feature to analyze potential usage of the technology in making even more precise and faster diagnostic outcomes. Such analysis would include developing subtle differences in biomarker profiles between drug-induced cholestasis and viral hepatitis (Moreno-Torres et al., 2024).

- **AI-Driven Diagnostics**

Based on supervised machine learning techniques, classifying liver injuries is done according to injury types like drug-induced or viral liver injury. Each model has been taught on a labeled dataset case of liver injuries and classified liver injury based on the enzyme levels, bilirubin concentration, or clinical history. For example, it has been used in the prediction of drug-induced liver injury (DILI) using the chemical properties of drugs and the liver cells to predict its effect (Mora et al., 2020). Due to the supervised learning, it is beneficial in classification of the liver injury types based on complex and multiple datasets. Additional studies, particularly those in recent times, have focused on SVM and random forest classifiers when comparing DIH and viral hepatitis as trained on patients' data from both laboratory tests and imaging results (Yan et al., 2022). Such models form a good early clinical diagnostic tool for DIH from other forms of similar clinical features liver diseases. To answer this need, deep learning, in particular convolutional neural networks (CNNs), is being tested with the possibility of analyzing changes in liver enzyme levels over time. This can be used with longitudinal testing of liver function to provide input into acute and chronic manifestations of DIH by temporal detection of changes in the liver function tests from hepatic injury. Patterns can be formed to correspond with certain drug exposure or viral infections, which will help clinicians decode hepatic enzyme dynamics for early identification and management (Hammann et al., 2019). Such systems are also capable of predicting the likelihood of liver injury progressing to more severe stages, such as cirrhosis or liver failure.

- **AI and Imaging Modalities**

Convolutional Neural networks- AI is very useful in diagnosis for every imaging modality such as CT scans or MRIs or ultrasound. All these methods are important as imaging techniques for visualizing abnormalities in the liver. However, such data must be derived by an expert radiologist as there is considerable variability and latencies in the diagnosis. Such imaging has much higher efficiency in processing and analyzing the images while locating lesions, inflammation, and even fibrosis in the liver. CNNs are being used to train specific imaging features to distinguish DIH from other liver diseases, with viral hepatitis being their most significant rival (Zhao et al., 2024).

AI-based CNNs can thus be suggested for assessing liver size, parenchymal texture, presence of fibrosis or cirrhosis. All of these can add to the diagnostic information extrapolated from biochemical tests. These models may thus serve as a decision-aiding system for radiologists in a clinical environment, increasing speed and accuracy in diagnosis. Such models can even detect minute lesions of fatty liver disease or fibrosis; these are usually chronic lesions or cases in DIH.

The value of artificial intelligence imaging analysis lies in the capability of such an analysis to differentiate DIH from viral hepatitis by virtue of the liver patterns seen on imaging. Although all these conditions have inflammation in the liver, their imaging characteristics differ. For instance, in the viral type, the injury will usually be more diffuse; in DIH, it may be localized, with certain specific patterns of fibrosis. AI algorithms analyze such patterns in much more

This is an Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

detail than manual interpretation, leading to greater accuracy in the diagnosis. By training on large datasets that include both DIH and viral hepatitis cases, AI can learn to recognize these distinguishing features and provide a more reliable diagnosis (Chen et al., 2022).

- **Case Studies and Performance Metrics**

Currently, several case studies establish that AI proves quite helpful in diagnosing DIH. One such example was a study which looked into prediction of drug-induced liver injury through machine learning. In this research, a random forest model attained an accuracy rate beyond 85% showcasing the ability to classify types of liver injury as per patients' data (Williams et al., 2020). Another study revealed that a deep learning model trained over imaging data from CT MRI scans can give sensitivity of 90% and specificity of 87% for liver fibrosis which is a frequent consequence of chronic drug-induced hepatotoxicity (Chierici et al., 2020).

The validation studies for AI models used in DIH are generally about an evaluation with respect to sensitivity, specificity, and ROC-AUC (Receiver Operating Characteristic-Area Under Curve). Sensitivity indicates the success of the model at identifying who is true positive, that is, whether he is a patient with DIH, while specificity refers to how good the model can get true negatives, that is, a model accused by a patient diagnosed with having no DIH. The ROC-AUC is a comprehensive measure of the model's diagnostic outcome across all thresholds, the more the values the better the accuracy. Emerging studies claim that machine learning models for detection of DIH have achieved more than over 0.9 ROC-AUC score, implying a very good diagnostic accuracy (Chen et al., 2022). Indeed, these metrics in skills show enough promise for AI to give accurate and reliable diagnostics in DIH and eventually lead to better patient outcomes by faster and more accurate detection of liver injury.




Figure 2: This flowchart illustrates the step-by-step process of AI-assisted diagnostics for Drug-Induced Liver Injury (DILI).

Advancements in AI for Differentiating Drug-Induced Hepatotoxicity (DIH) and Viral Hepatitis

Artificial Intelligence has made great progressions in the health sector, especially when diagnosing and differentiating complicated diseases like Drug-Induced Hepatitis (DIH) and Viral Hepatitis. Such-like conditions require careful differentiation, as they warrant two entirely different modes of treatment. But more importantly, it presents vast potential in the analysis of massive datasets, the integration of diverse information sources, and the detection of phenomena that human clinicians might overlook; thus, identifying it as a valuable resource to fulfill such goals. AI itself has rapid progress in the field of differential diagnosis, especially in difficulty differentiating drug-induced hepatotoxicity (DIH) from viral hepatitis.

Decision trees and random forests are typical algorithms employed in tasks of classification of hepatotoxicity prediction. The good handling of feature selection, and offer interpretation, which is vital in a clinical setting, are merits of these models. A research example like Su et al. (2019) developed a multi-dose computational model based on toxicogenomic data as well as by making use of the decision trees to model and predict hepatotoxicity under various drug doses. Their work indicated that it is possible for decision trees to be resourceful, as they proved to produce great accuracy upon gene expression profile incorporation; thereby backing their purpose in hepatotoxicity classification.

Of course, deep learning models, particularly neural networks, continue to lead to predicting DIH. The "Deep DILI," which uses molecular-level representations driven by deep learning for predicting DIH, was introduced by Li et al. (2021). An example is Yang et al. (2024), who used a neural network architecture with molecular fingerprints that classify liver injuries as either drug-induced or viral-infection induced (e.g., hepatitis), signaling the improvement in sensitivity and specificity associated with deep neural networks.

The authors Çelik & Karaduman (2023) employed AI methods for prediction in an outcome that made use of clinical, laboratory, and quantitative structure-activity relationship (QSAR) assays. This prediction improved prediction

This is an Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

E-ISSN : 2962-1658
Volume 4, Number 3, July , 2025
https://doi.org/10.47709/ijmdsa.v4i3.5291

of hepatotoxicity in managing and differentiating between drug-induced injury and viral cases. maelstrom on fusion with clinical chemistry values, imaging reports, and biomarkers. There is growing evidence that improving the quality of diagnostic performance involves an algorithmic combined approach.

Integration of multimodal data may perhaps be combined with a clinical plus imaging and laboratory and genetic data source for enhancement of the accuracy in diagnosis. Different forms of studies pursued by research are the integration of different forms of patient data that approach full understanding of the patient's health to make distinctions between DIH and viral hepatitis. Rathee et al. (2022) produced DILI-C, a new AI classifier intended to mine literature data for drug-induced liver injury, combining data from Electronic Health Records with patient demography. This model was created to semiautomatically allow methodology processing complex EHR and biomarkers in a step up to enhanced predictive ability of AI systems in identifying DIH and differentiating it from viral hepatitis. Feng et al. proposed a deep learning model that used gene expression data as well as clinical biomarkers such as liver enzymes and bilirubin levels to predict DIH before clinical manifestation of symptoms. This prediction model works in differentiating DIH from viral hepatitis, which often shows similarity with respect to liver inflammation and enzyme elevations. Fu et al. (2023) predict chronicity in drug-induced liver injury (DILI) using a multimodal approach wherein the radiomic features extracted from the MRIs of the liver are combined with clinical and histopathological data.

Their study indicated that by creating machine learning models which integrate imaging and clinical data, it is possible to improve the accuracy of the diagnosis of liver injury and to differentiate DIH from chronic viral hepatitis. Zhong et al. (2021) applied machine learning techniques to clinical and radiological data to detect and differentiate the liver injury from tuberculosis drugs such as Rifampicin from those resulting from viral hepatitis. Their research shows the power of multimodal models that bring both clinical data and radiologic imaging together.

AI models need to be clinically validated for hepatotoxicity prediction for use in heterogeneous patient populations. Previous studies have also reported comparisons of the performance of the AI models with traditional diagnostic techniques like liver biopsy or serologic tests for hepatitis. Baek et al. (2023) earlier applied Mask R-CNN-based deep learning in a rat model of drug-induced liver injury. The results illustrate how AI has the potential to surpass conventional histopathological methods in accurately diagnosing DIH, providing an alternative to biopsy-based diagnosis. According to Moore et al. (2021), machine learning models were compared with traditional clinical diagnoses (like liver enzyme tests) in terms of their accuracy for hepatotoxicity detection in patients receiving non-steroidal anti-inflammatory drug (NSAID) therapy. Results showed that machine learning proved superior to the conventional method for early detection, with a better sensitivity.

Different types of AI techniques used in DILI differentiation.

- **Machine Learning (ML) Techniques for Drug-Induced Hepatotoxicity (DIH) Prediction**

Long association with clinic data, laboratory results, and patient further information has proposed Machine Learning (ML) to be an effective predictor for Drug-Induced Hepatotoxicity-DIH with variety and volume of input data. Integration of Large data sets into ML models has proven to be important for early warning systems for liver injury by drugs (medications). Of the available prominent algorithms used in predicting DIH situation, the Random Forests (RF) have been beneficial for categorizing patients as "DIH" or "Non-DIH" based on their levels of liver enzymes (such as ALT, AST, bilirubin), drug exposure, and demographic details. For instance, Kim et al. (2021), demonstrated the application of RF in hepatotoxicity tests in patients taking Nilotinib; liver enzymes and drug metabolites were identified as important features for the prediction process.

Another popular ML classification that purportedly differentiates DIH from other liver injuries like those caused by viral hepatitis is SVM. Hong et al. (2017) demonstrated that SVM might classify cases adequately even when biomarker overlaps occur, which is one of the usual problems in DIH diagnosis. Besides, Gradient Boosting Machines such as XGBoost and LightGBM can effectively solve large and challenging problems and are thus often used in cases of DIH predictions. These guaranteed linkages of cumulative drug dosage and/or partly missing data, as emphasized by Minerali et al. (2020), who showed that GBM performed best in terms of accuracy compared with all other ML models. In contrast, K-Nearest Neighbors (KNN), which is a non-parametric algorithm, makes a much simpler prediction of DIH cases by depending on the similarity to the already observed ones. However, KNN is not very usable for large datasets as it is very limited in scalability, according to Jiang et al. (2023). Thus, these modern ML techniques are not only used for diagnosing DIH but are also utilized in severity assessment, prediction of outcomes for patients, and creating individualized models for risks and therapy choices which collectively lead to better accuracy and efficiency in managing DIH.

- **Deep Learning (DL) Approaches in DIH Prediction**

Deep Learning (DL) methods have revolutionized the medical field in diagnosis, particularly for unstructured data, such as medical images and genomic sequences, where traditional methods fail. Convolutional Neural Networks (CNN), one major architecture of DL, performs excellently for liver imaging data from CT and MRI modalities. CNN detects very fine patterns of damage to hepatocytes and inflammation, which are features crucial in diagnosing DIH. In fact, based on the research findings of Zhong et al. (2021), CNNs in terms of diagnostic capabilities can identify liver injuries among patients with tuberculosis. Also, RNNs are fitted well beyond normal deep learning applications:

This is an Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

E-ISSN : 2962-1658
Volume 4, Number 3, July , 2025
https://doi.org/10.47709/ijmdsa.v4i3.5291

recurrent neural networks are an effective type of architecture specifically meant for modeling time-series data, such as the sequential measurements of liver enzyme levels. Xiao et al. (2024) said that an RNN can possibly forecast DIH onset based on how liver enzyme levels have been changing over time. Besides, transformer models, which are really emerging as an excellent bridge in processing sequential data with non-sequential data, now enable the more efficient and powerful use of digital personal medical histories coupled with imaging results or lab data. This will definitely bring a disease such as DIH closer to a more personalized and comprehensive definition and diagnosis and make it easier for individualized treatment strategies.

In another form of DL model, autoencoders, the authors learn features from complex genomic data and, according to Liu et al. (2023), might reveal genetic risk markers for DIH. They will be most important in finding people who are genetically vulnerable to liver injury. These models allow high-level integration of multiomics data, that is, combining genomics, proteomics, and metabolomics data, through DL techniques for inadequate patient-level perspectives in risk for DIH. Through real-time imaging analysis and faster clinical decision-making, DL is transforming DIH detection and management by enabling earlier and more accurate diagnoses.

- **Natural Language Processing (NLP) and Explainable AI (XAI) in DIH Prediction**

Natural Language Processing (NLP) is one of the most significant enablers of Drug Induced Hepatotoxicity (DIH) detection through the extraction of certain key information from unstructured-clinical data. Named Entity Recognition (NER) identifies terms like "hepatotoxicity" and "elevated ALT" from clinical notes and is beneficial to an early DIH diagnosis (Adeluwa, 2021). Text classification models, such as BERT, are reflective tools that analyze clinical reports and pharmacovigilance data for distinguishing hepatotoxicity from other negative ADRs (Fu et al., 2023). Topic modeling further exposes large volumes of data to revealing drugs most frequently observed in association with liver injury. Also, Sentiment analysis explores patient-reported outcomes to evaluate the degree and evolution of symptoms that give a well-defined understanding of DIH from a different perspective.

On the other side, AI models become further complicate and Explanatory AI, XAI, makes the understanding and trust of the models by clinicians viable. The results are sufficiently clarified about predictions through SHAP and LIME regarding the most prominent features like liver enzymes that constitute DIH risk assessments (Tang et al. 2023). XAI tools are like these making AI predictions interpretable to nurture clinical decisions and make it sound to clinicians to incorporate AI into their practice. Together with NLP, these enhance the trustworthiness and usability of AI models designed for DIH detection and management, thus improving early diagnostics and patient care.

To conclude, these techniques have demonstrated impressive performance in diagnosing DIH, improving accuracy, and offering personalized treatment options. However, the various AI models differ in their strengths, data handling capabilities, and performance metrics. The following table summarizes key AI models used in DIH prediction, highlighting their strengths, performance metrics, and relevant references.

Table 4. Comparison of AI Models for Drug-Induced Hepatotoxicity (DIH) Prediction, highlighting their strengths, performance metrics.

AI Model	Type	Strengths	Performance Metrics	References
Random Forest (RF)	Machine Learning	Effective with structured data, handling large datasets, robust to overfitting	Accuracy, Sensitivity, Specificity, Feature Importance	Kim et al. (2021)
Support Vector Machine (SVM)	Machine Learning	Good for high-dimensional data, works well with overlapping biomarkers	Accuracy, Precision, Recall, F1-Score	Hong et al. (2017)
XGBoost	Gradient Boosting	Handles missing values, works well with complex datasets	Accuracy, AUC (Area Under the Curve), Precision, Recall	Minerali et al. (2020)
LightGBM	Gradient Boosting	Faster training time, handles large datasets with high dimensionality	Accuracy, AUC, Precision, Recall	Minerali et al. (2020)
K-Nearest Neighbors (KNN)	Machine Learning	Simple, effective for small datasets, easy to interpret	Accuracy, Sensitivity, Specificity	Jiang et al. (2023)
Convolutional Neural Networks (CNN)	Deep Learning	Best for image data, detects subtle liver damage patterns in imaging	Accuracy, AUC, Sensitivity, Specificity	Zhong et al. (2021)
Recurrent Neural Networks (RNN)	Deep Learning	Effective for sequential data, e.g., liver enzyme trends	Accuracy, Sensitivity, Recall	Xiao et al. (2024)

This is an Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Transformer Models	Deep Learning	Integrates diverse patient data (clinical, imaging, lab)	Accuracy, AUC, Precision, Recall	General trend in DL research
Autoencoders	Deep Learning	Identifies genetic risk markers, useful for genomic data	Accuracy, AUC, Sensitivity	Liu et al. (2023)
SHAP & LIME	Explainable AI	Provides interpretability for complex models, boosts clinician trust	Feature Importance, Explanation Consistency	Tang et al. (2023)

CONCLUSION

AI employs approaches or models that apply machine learning and imaging for the quality of DILI diagnosis. DILI diagnosis is the most complicated because non-specifically overlapping symptoms follow those of viral hepatitis, posing difficult conditions for accurate diagnosis. AI shows how to empower diagnostic capacity by enhancing or perfecting the quality of machine learning algorithms and imaging applications.

The key-algorithms employed include Random Forests, Support Vector Machines (SVM), and Gradient Boosting Machines (GBMs). They have all classified DIH from viral hepatitis successfully within the problem domain. The models used various parameters, including clinical data, liver enzyme levels, and patient demographics along with drug exposure background, to predict accurately. Besides that, AI models integrated with biomarkers ALT, AST, and bilirubin levels can aid in DIH from standard viral hepatitis interpretation giving rise to non-invasive diagnostic tools. This is in addition to deep learning techniques in medical imaging, such as Convolutional Neural Networks (CNNs). This technology examines various liver scans (MRI, CT, and ultrasound) to analyze injury patterns unique to DIH and viral hepatitis.

Artificial intelligence in the diagnosis of DIH offers multiple potential clinics advantages. First, AI has the potential to greatly enhance diagnostic accuracy, shorten diagnosis time, and deter misdiagnoses, which places patients at risk for the initiation of inappropriate therapies. Compared with human clinicians, artificial intelligence has the potential to mine enormous databases to discover tiny patterns that might not be obvious and visible in the eyes of those in the profession. It is potentially invaluable for helping to make decisions when complicated cases are considered-by degrees when the clinical manifestation resembles those of other liver diseases, such as viral hepatitis. Further, it would lessen invasive liver biopsy, historically considered a gold standard for confirming DIH, by allowing prediction based on clinical, laboratory, and imaging data, empowering early intervention to improve management for patients suspected of having DIH. These non-invasive diagnostics would significatively change practice and patient outcomes for the time saved in treatment and fewer complications attributable to the delay in diagnosis. There are still some challenges involved in putting AI tools into clinical practice for DIH diagnosis.

While larger sets of data might be helpful in making the models more robust and generalizable, particularly in including rare drug-induced hepatotoxicity, which most probably will not be represented in existing datasets, validation of models across heterogeneous populations and healthcare settings will be essential for the AI diagnostic tool to perform as envisaged in the real-world scenarios. For AI integration into clinical practice further work is necessary. For example, the AI models need to be compatible with the current EHR systems, and clinicians should be educated in proper interpretation and application before the actual usage of the AI instrument. XAI becomes an important aspect to help in the trust improvement among clinicians about AI recommendations. Further, individualization of diagnostic models can be developed for different patients including genetic profile and drug history which would raise the accuracy of AI in detecting DIH.

In conclusion, AI has to bring in some changes to the diagnosis of DIH, now going at complementing and complementing traditional diagnosis with faster, more accurate, and less invasive diagnostic solutions. However, AI has yet much further to go regarding data collection, model validation, and clinical integration before bringing all this to fruition for the greater improvement of patient care and outcome in the management of DIH and its differentiation from viral hepatitis.

REFERENCE

Adeluwa, T. P. (2021). *Using Machine Learning On Diverse Datasets To Predict Drug-Induced Liver Injury* (Master's thesis, The University of North Dakota).

Baek, E. B., Lee, J., Hwang, J. H., Park, H., Lee, B. S., Kim, Y. B., Jun, S. Y., Her, J., Son, H. Y., & Cho, J. W. (2023). Application of multiple-finding segmentation utilizing Mask R-CNN-based deep learning in a rat model of drug-induced liver injury. *Scientific reports*, *13*(1), 17555. https://doi.org/10.1038/s41598-023-44897-8

Brony, M., Alivi, M. A., Syed, M. A. M., & Dharejo, N. (2024). A Systematic Review on Social Media Health Communications and Behavioural Development among Indians in the COVID-19 Context. Studies in Media and Communication, 12(2), 37-49.

This is an Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Brony, M., Alivi, M. A., Syed, M. A. M., Dharejo, N., & Jiaqing, X. (2024). A systematic review on social media utilization by health communicators in India: Insights from COVID-19 pandemic. Online Journal of Communication and Media Technologies, 14(4), e202449. https://doi.org/10.30935/ojcmt/15007

Chen, Z., Jiang, Y., Zhang, X., Zheng, R., Qiu, R., Sun, Y., Zhao, C., & Shang, H. (2022). The prediction approach of drug-induced liver injury: response to the issues of reproducible science of artificial intelligence in real-world applications. Briefings in bioinformatics, 23(4), bbac196. https://doi.org/10.1093/bib/bbac196

Chen, Z., Jiang, Y., Zhang, X., Zheng, R., Qiu, R., Sun, Y., Zhao, C., & Shang, H. (2022). ResNet18DNN: prediction approach of drug-induced liver injury by deep neural network with ResNet18. Briefings in bioinformatics, 23(1), bbab503. https://doi.org/10.1093/bib/bbab503

Chen, Z., Zhao, M., You, L., Zheng, R., Jiang, Y., Zhang, X., Qiu, R., Sun, Y., Pan, H., He, T., Wei, X., Chen, Z., Zhao, C., & Shang, H. (2022). Developing an artificial intelligence method for screening hepatotoxic compounds in traditional Chinese medicine and Western medicine combination. Chinese medicine, 17(1), 58. https://doi.org/10.1186/s13020-022-00617-4

Chierici, M., Francescatto, M., Bussola, N., Jurman, G., & Furlanello, C. (2020). Predictability of drug-induced liver injury by machine learning. Biology direct, 15(1), 3. https://doi.org/10.1186/s13062-020-0259-4

Datta, A., Flynn, N. R., Barnette, D. A., Woeltje, K. F., Miller, G. P., & Swamidass, S. J. (2021). Machine learning liver-injuring drug interactions with non-steroidal anti-inflammatory drugs (NSAIDs) from a retrospective electronic health record (EHR) cohort. PLoS computational biology, 17(7), e1009053. https://doi.org/10.1371/journal.pcbi.1009053

Dharejo, N., Alivi, M. A., Rahamad, M. S., Jiaqing, X., & Brony, M. (2023). Effects of Social Media Use on Adolescent Psychological Well-Being: A Systematic Literature Review. International Journal of Interactive Mobile Technologies, 17(20).

Feng, C., Chen, H., Yuan, X., Sun, M., Chu, K., Liu, H., & Rui, M. (2019). Gene Expression Data Based Deep Learning Model for Accurate Prediction of Drug-Induced Liver Injury in Advance. Journal of chemical information and modeling, 59(7), 3240–3250. https://doi.org/10.1021/acs.jcim.9b00143

Fu, H., Shen, Z., Lai, R., Zhou, T., Huang, Y., Zhao, S., ... & Xie, Q. (2023). Clinic-radiomics model using liver magnetic resonance imaging helps predict chronicity of drug-induced liver injury. Hepatology International, 17(6), 1626-1636.

Gonzalez-Jimenez, A., Suzuki, A., Chen, M., Ashby, K., Alvarez-Alvarez, I., Andrade, R. J., & Lucena, M. I. (2021). Drug properties and host factors contribute to biochemical presentation of drug-induced liver injury: a prediction model from a machine learning approach. Archives of toxicology, 95(5), 1793–1803. https://doi.org/10.1007/s00204-021-03013-3

Hammann, F., Schöning, V., & Drewe, J. (2019). Prediction of clinically relevant drug-induced liver injury from structure using machine learning. Journal of applied toxicology : JAT, 39(3), 412–419. https://doi.org/10.1002/jat.3741

Hong, H., Thakkar, S., Chen, M., & Tong, W. (2017). Development of Decision Forest Models for Prediction of Drug-Induced Liver Injury in Humans Using A Large Set of FDA-approved Drugs. Scientific reports, 7(1), 17311. https://doi.org/10.1038/s41598-017-17701-7

Hussin, S. K., Abdelmageid, S. M., Alkhalil, A., Omar, Y. M., Marie, M. I., & Ramadan, R. A. (2021). Handling imbalance classification virtual screening big data using machine learning algorithms. Complexity, 2021(1), 6675279.

Jaganathan, K., Tayara, H., & Chong, K. T. (2021). Prediction of Drug-Induced Liver Toxicity Using SVM and Optimal Descriptor Sets. International journal of molecular sciences, 22(15), 8073. https://doi.org/10.3390/ijms22158073

Jiang, J., van Ertvelde, J., Ertaylan, G., Peeters, R., Jennen, D., de Kok, T. M., & Vinken, M. (2023). Unraveling the mechanisms underlying drug-induced cholestatic liver injury: identifying key genes using machine learning techniques on human in vitro data sets. Archives of Toxicology, 97(11), 2969-2981.

Jiaqing, X., Alivi, M. A., Mustafa, S. E., & Dharejo, N. (2023). The Impact of Social Media on Women's Body Image Perception: A Meta-Analysis of Well-being Outcomes. International Journal of Interactive Mobile Technologies, 17(20).

Jin, Y., Xi, L., Wei, Y., & Wu, X. (2022). Recognition of specific types of drug-induced liver injury using random forest algorithm: the importance of individual serum bile acid level. Journal of Chinese Pharmaceutical Sciences, 31(9).

Jun, G., Xu, J., Alivi, M. A., Zhewen, F., Dharejo, N., & Brony, M. (2025). Impacts of digital media on children's well-being: A bibliometric analysis. Online Journal of Communication and Media Technologies, 15(1), e202501. https://doi.org/10.30935/ojcmt/15696

Kang, M. G., & Kang, N. S. (2021). Predictive Model for Drug-Induced Liver Injury Using Deep Neural Networks Based on Substructure Space. Molecules (Basel, Switzerland), 26(24), 7548. https://doi.org/10.3390/molecules26247548

Kelleci Çelik, F., & Karaduman, G. (2023). Machine learning-based prediction of drug-induced hepatotoxicity: An OvA-QSTR approach. Journal of Chemical Information and Modeling, 63(15), 4602-4614.

This is an Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Kim, J. S., Han, J. M., Cho, Y. S., Choi, K. H., & Gwak, H. S. (2021). Machine Learning Approaches to Predict Hepatotoxicity Risk in Patients Receiving Nilotinib. Molecules (Basel, Switzerland), 26(11), 3300. https://doi.org/10.3390/molecules26113300

Kurosaki, K., & Uesawa, Y. (2022). Development of in silico prediction models for drug-induced liver malignant tumors based on the activity of molecular initiating events: Biologically interpretable features. The Journal of toxicological sciences, 47(3), 89–98. https://doi.org/10.2131/jts.47.89

Lewis, J. H., Korkmaz, S. Y., Rizk, C. A., & Copeland, M. J. (2024). Diagnosis, prevention and risk-management of drug-induced liver injury due to medications used to treat mycobacterium tuberculosis. Expert Opinion on Drug Safety, 23(9), 1093-1107.

Li, T. (2021). Predicting Drug-Induced Liver Injury With Artificial Intelligence (Doctoral dissertation, University of Arkansas at Little Rock).

Li, T., Tong, W., Roberts, R., Liu, Z., & Thakkar, S. (2021). DeepDILI: Deep Learning-Powered Drug-Induced Liver Injury Prediction Using Model-Level Representation. Chemical research in toxicology, 34(2), 550–565. https://doi.org/10.1021/acs.chemrestox.0c00374

Liu, A., Walter, M., Wright, P., Bartosik, A., Dolciami, D., Elbasir, A., Yang, H., & Bender, A. (2021). Prediction and mechanistic analysis of drug-induced liver injury (DILI) based on chemical structure. Biology direct, 16(1), 6. https://doi.org/10.1186/s13062-020-00285-0

Liu, Y., Gao, H., & He, Y. D. (2020). A compound attributes-based predictive model for drug induced liver injury in humans. PloS one, 15(4), e0231252. https://doi.org/10.1371/journal.pone.0231252

Liu, Z., Li, T., Connor, S., Thakkar, S., Roberts, R., & Tong, W. (2022). Best practice and reproducible science are required to advance artificial intelligence in real-world applications. Briefings in bioinformatics, 23(4), bbac237. https://doi.org/10.1093/bib/bbac237

Lu, F., Meng, Y., Song, X., Li, X., Liu, Z., Gu, C., ... & Qi, X. (2024). Artificial Intelligence in Liver Diseases: Recent Advances. Advances in Therapy, 41(3), 967-990.

Ma, H., An, W., Wang, Y., Sun, H., Huang, R., & Huang, J. (2021). Deep Graph Learning with Property Augmentation for Predicting Drug-Induced Liver Injury. Chemical research in toxicology, 34(2), 495–506. https://doi.org/10.1021/acs.chemrestox.0c00322

Martínez, J. A., Alonso-Bernáldez, M., Martínez-Urbistondo, D., Vargas-Nuñez, J. A., Ramírez de Molina, A., Dávalos, A., & Ramos-Lopez, O. (2022). Machine learning insights concerning inflammatory and liver-related risk comorbidities in non-communicable and viral diseases. World journal of gastroenterology, 28(44), 6230–6248. https://doi.org/10.3748/wjg.v28.i44.6230

Minerali, E., Foil, D. H., Zorn, K. M., Lane, T. R., & Ekins, S. (2020). Comparing machine learning algorithms for predicting drug-induced liver injury (DILI). Molecular pharmaceutics, 17(7), 2628-2637.

Mohsen, A., Tripathi, L. P., & Mizuguchi, K. (2021). Deep learning prediction of adverse drug reactions in drug discovery using open TG–GATEs and FAERS databases. Frontiers in Drug Discovery, 1, 768792.

Moore, R., Ashby, K., Liao, T. J., & Chen, M. (2021). Machine Learning to Identify Interaction of Single-Nucleotide Polymorphisms as a Risk Factor for Chronic Drug-Induced Liver Injury. International journal of environmental research and public health, 18(20), 10603. https://doi.org/10.3390/ijerph182010603

Mora, J. R., Marrero-Ponce, Y., García-Jacas, C. R., & Suarez Causado, A. (2020). Ensemble Models Based on QuBiLS-MAS Features and Shallow Learning for the Prediction of Drug-Induced Liver Toxicity: Improving Deep Learning and Traditional Approaches. Chemical research in toxicology, 33(7), 1855–1873. https://doi.org/10.1021/acs.chemrestox.0c00030

Moreno-Torres, M., López-Pascual, E., Rapisarda, A., Quintás, G., Drees, A., Steffensen, I. L., Luechtefeld, T., Serrano-Candelas, E., de Lomana, M. G., Gadaleta, D., Dirven, H., Vinken, M., & Jover, R. (2024). Novel clinical phenotypes, drug categorization, and outcome prediction in drug-induced cholestasis: Analysis of a database of 432 patients developed by literature review and machine learning support. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 174, 116530. https://doi.org/10.1016/j.biopha.2024.116530

Puri M. (2020). Automated Machine Learning Diagnostic Support System as a Computational Biomarker for Detecting Drug-Induced Liver Injury Patterns in Whole Slide Liver Pathology Images. Assay and drug development technologies, 18(1), 1–10. https://doi.org/10.1089/adt.2019.919

Rao, M., Nassiri, V., Alhambra, C., Snoeys, J., Van Goethem, F., Irrechukwu, O., Aleo, M. D., Geys, H., Mitra, K., & Will, Y. (2023). AI/ML Models to Predict the Severity of Drug-Induced Liver Injury for Small Molecules. Chemical research in toxicology, 36(7), 1129–1139. https://doi.org/10.1021/acs.chemrestox.3c00098

Rathee, S., MacMahon, M., Liu, A., Katritsis, N. M., Youssef, G., Hwang, W., Wollman, L., & Han, N. (2022). DILI C : An AI-Based Classifier to Search for Drug-Induced Liver Injury Literature. Frontiers in genetics, 13, 867946. https://doi.org/10.3389/fgene.2022.867946

Su, R., Wu, H., Xu, B., Liu, X., & Wei, L. (2019). Developing a Multi-Dose Computational Model for Drug-Induced Hepatotoxicity Prediction Based on Toxicogenomics Data. IEEE/ACM transactions on computational biology and bioinformatics, 16(4), 1231–1239. https://doi.org/10.1109/TCBB.2018.2858756

This is an Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Tang, T., Gan, X., Zhou, L., Pu, K., Wang, H., Dai, W., ... & Zhang, Y. (2023). Exploring the Hepatotoxicity of Drugs through Machine Learning and Network Toxicological Methods. Current Bioinformatics, 18(6), 484-496.

Vall, A., Sabnis, Y., Shi, J., Class, R., Hochreiter, S., & Klambauer, G. (2021). The Promise of AI for DILI Prediction. Frontiers in artificial intelligence, 4, 638410. https://doi.org/10.3389/frai.2021.638410

Villanueva-Paz, M., Niu, H., Segovia-Zafra, A., Medina-Caliz, I., Sanabria-Cabrera, J., Lucena, M. I., ... & Alvarez-Alvarez, I. (2021). Critical review of gaps in the diagnosis and management of drug-induced liver injury associated with severe cutaneous adverse reactions. Journal of Clinical Medicine, 10(22), 5317.

Wang, K., Zhang, L., Li, L., Wang, Y., Zhong, X., Hou, C., Zhang, Y., Sun, C., Zhou, Q., & Wang, X. (2022). Identification of Drug-Induced Liver Injury Biomarkers from Multiple Microarrays Based on Machine Learning and Bioinformatics Analysis. International journal of molecular sciences, 23(19), 11945. https://doi.org/10.3390/ijms231911945

Williams, D. P., Lazic, S. E., Foster, A. J., Semenova, E., & Morgan, P. (2020). Predicting Drug-Induced Liver Injury with Bayesian Machine Learning. Chemical research in toxicology, 33(1), 239–248. https://doi.org/10.1021/acs.chemrestox.9b00264

Wu, W., Qian, J., Liang, C., Yang, J., Ge, G., Zhou, Q., & Guan, X. (2023). GeoDILI: A Robust and Interpretable Model for Drug-Induced Liver Injury Prediction Using Graph Neural Network-Based Molecular Geometric Representation. Chemical research in toxicology, 36(11), 1717–1730. https://doi.org/10.1021/acs.chemrestox.3c00199

Xiao, Y., Chen, Y., Huang, R., Jiang, F., Zhou, J., & Yang, T. (2024). Interpretable machine learning in predicting drug-induced liver injury among tuberculosis patients: model development and validation study. BMC medical research methodology, 24(1), 92. https://doi.org/10.1186/s12874-024-02214-5

Yan, B., Ye, X., Wang, J., Han, J., Wu, L., He, S., Liu, K., & Bo, X. (2022). An Algorithm Framework for Drug-Induced Liver Injury Prediction Based on Genetic Algorithm and Ensemble Learning. Molecules (Basel, Switzerland), 27(10), 3112. https://doi.org/10.3390/molecules27103112

Yang, Q., Zhang, S., & Li, Y. (2024). Deep Learning Algorithm Based on Molecular Fingerprint for Prediction of Drug-Induced Liver Injury. Toxicology, 502, 153736. https://doi.org/10.1016/j.tox.2024.153736

Yen, J. S., Hu, C. C., Huang, W. H., Hsu, C. W., Yen, T. H., & Weng, C. H. (2021). An artificial intelligence algorithm for analyzing acetaminophen-associated toxic hepatitis. Human & Experimental Toxicology, 40(11), 1947-1954.

Zhan, X., Wang, F., & Gevaert, O. (2022). Reliably Filter Drug-Induced Liver Injury Literature With Natural Language Processing and Conformal Prediction. IEEE journal of biomedical and health informatics, 26(10), 5033–5041. https://doi.org/10.1109/JBHI.2022.3193365

Zhao, Y., Zhang, Z., Kong, X., Wang, K., Wang, Y., Jia, J., Li, H., & Tian, S. (2024). Prediction of Drug-Induced Liver Injury: From Molecular Physicochemical Properties and Scaffold Architectures to Machine Learning Approaches. Chemical biology & drug design, 104(2), e14607. https://doi.org/10.1111/cbdd.14607

Zhong, T., Zhuang, Z., Dong, X., Wong, K. H., Wong, W. T., Wang, J., ... & Liu, S. (2021). Predicting Antituberculosis Drug–Induced Liver Injury Using an Interpretable Machine Learning Method: Model Development and Validation Study. JMIR medical informatics, 9(7),

This is an Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.